What is Wedbush’s Estimate for Nuvation Bio FY2027 Earnings?

Nuvation Bio Inc. (NYSE:NUVB) – Analysts at Wedbush raised their FY2027 earnings estimates for Nuvation Bio in a research note issued to investors on Wednesday, November 26th. Wedbush analyst D. Nierengarten now expects that the company will earn $0.00 per share for the year, up from their prior estimate of ($0.23). Wedbush currently has a “Outperform” rating and a $6.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s FY2028 earnings at $0.68 EPS.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%.The business had revenue of $13.12 million during the quarter, compared to analysts’ expectations of $7.48 million.

Several other analysts have also recently commented on NUVB. Citigroup restated a “market outperform” rating on shares of Nuvation Bio in a research note on Tuesday, November 4th. JMP Securities set a $10.00 price target on shares of Nuvation Bio in a report on Thursday, November 20th. Truist Financial set a $11.00 price objective on shares of Nuvation Bio in a research report on Monday, November 24th. Citizens Jmp lifted their price objective on Nuvation Bio from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, November 20th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Nuvation Bio in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nuvation Bio currently has a consensus rating of “Moderate Buy” and an average price target of $9.67.

Nuvation Bio Stock Performance

NYSE:NUVB opened at $7.88 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of -12.31 and a beta of 1.57. The firm’s fifty day moving average price is $4.82 and its 200 day moving average price is $3.30. Nuvation Bio has a 1-year low of $1.54 and a 1-year high of $8.24.

Institutional Trading of Nuvation Bio

Several institutional investors and hedge funds have recently made changes to their positions in NUVB. CIBC Bancorp USA Inc. bought a new position in shares of Nuvation Bio during the third quarter worth about $98,000. Caitong International Asset Management Co. Ltd increased its holdings in Nuvation Bio by 811.7% in the third quarter. Caitong International Asset Management Co. Ltd now owns 39,950 shares of the company’s stock valued at $148,000 after buying an additional 35,568 shares during the last quarter. Connective Capital Management LLC acquired a new stake in Nuvation Bio during the third quarter valued at approximately $369,000. Armistice Capital LLC raised its stake in Nuvation Bio by 359.2% during the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock valued at $8,495,000 after buying an additional 1,796,000 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in Nuvation Bio during the 3rd quarter worth approximately $711,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Nuvation Bio

In other Nuvation Bio news, insider Dongfang Liu sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $8.00, for a total value of $80,000.00. Following the sale, the insider owned 18,000 shares of the company’s stock, valued at approximately $144,000. This represents a 35.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary Hattersley sold 100,000 shares of the firm’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 170,000 shares of company stock worth $877,800 in the last three months. Corporate insiders own 29.93% of the company’s stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.